Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Possible Impact of Merck Acqusition of Cubist on the Trius CVR

I was just asked about the potential impact on the value of the Trius CVR of the Merck acquisition of…
Read more…

Cubist Pharmaceuticals: An Overview Based on a Recent Company Presentation (CBST, No Opinion)

Introduction

I recently was invited to attend a broker sponsored conference for biotechnology companies. Altogether, there were 116 companies presenting at…
Read more…

Trius: Will there be a Higher Bidder and what is the CVR Worth? (TSRX; $14.10)

What is the CVR Worth?
I wanted to address some additional points in regard to the proposed acquisition of Trius (TSRX)…
Read more…

Trius Therapeutics to be Acquired by Cubist (TSRX: $13.66)

Implications for Trius Shareholders
Cubist Pharmaceuticals (CBST) and Trius Therapeutics, Inc. (TSRX) announced that they have signed a definitive agreement under…
Read more…

Thoughts on the Growing Crisis of Bacterial Resistance to Antibiotics

Investment Overview
We hear constantly from the media about problems with bacterial resistance to antibiotics. I think that this is an…
Read more…

Trius' (TSRX) Tedizolid Has Blockbuster Potential for MRSA Infections

Trius Therapeutics TSRX) is in late stage clinical development of its new antibiotic, tedizolid, for treatment of MRSA infections that…
Read more…